CO2022001218A2 - Composición de inhibidor micromolecular de pi4kiiiα, método de preparación y uso - Google Patents

Composición de inhibidor micromolecular de pi4kiiiα, método de preparación y uso

Info

Publication number
CO2022001218A2
CO2022001218A2 CONC2022/0001218A CO2022001218A CO2022001218A2 CO 2022001218 A2 CO2022001218 A2 CO 2022001218A2 CO 2022001218 A CO2022001218 A CO 2022001218A CO 2022001218 A2 CO2022001218 A2 CO 2022001218A2
Authority
CO
Colombia
Prior art keywords
composition
pi4kiiiα
preparation
micromolecular inhibitor
pharmaceutical composition
Prior art date
Application number
CONC2022/0001218A
Other languages
English (en)
Spanish (es)
Inventor
Fude Huang
Feng Wang
Shu Yang
Changping Jiao
Xiaojun Zhou
Original Assignee
Nuo Beta Pharmaceutical Tech Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuo Beta Pharmaceutical Tech Shanghai Co Ltd filed Critical Nuo Beta Pharmaceutical Tech Shanghai Co Ltd
Publication of CO2022001218A2 publication Critical patent/CO2022001218A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/285—Arsenic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CONC2022/0001218A 2019-07-05 2022-02-07 Composición de inhibidor micromolecular de pi4kiiiα, método de preparación y uso CO2022001218A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019094831 2019-07-05
PCT/CN2020/100377 WO2021004422A1 (zh) 2019-07-05 2020-07-06 小分子PI4KIIIα抑制剂组合物、其制备方法及用途

Publications (1)

Publication Number Publication Date
CO2022001218A2 true CO2022001218A2 (es) 2022-05-20

Family

ID=74115038

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0001218A CO2022001218A2 (es) 2019-07-05 2022-02-07 Composición de inhibidor micromolecular de pi4kiiiα, método de preparación y uso

Country Status (15)

Country Link
US (1) US20230115711A1 (cg-RX-API-DMAC7.html)
EP (1) EP3995134A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022538505A (cg-RX-API-DMAC7.html)
KR (1) KR20220071175A (cg-RX-API-DMAC7.html)
CN (2) CN114555056B (cg-RX-API-DMAC7.html)
AU (1) AU2020309681A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022000155A2 (cg-RX-API-DMAC7.html)
CA (1) CA3149104A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022001218A2 (cg-RX-API-DMAC7.html)
IL (1) IL289586A (cg-RX-API-DMAC7.html)
MX (1) MX2022000287A (cg-RX-API-DMAC7.html)
PE (1) PE20220942A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022550254A1 (cg-RX-API-DMAC7.html)
TW (1) TW202126294A (cg-RX-API-DMAC7.html)
WO (1) WO2021004422A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114685566A (zh) * 2020-12-31 2022-07-01 江苏挪贝肽医药科技有限公司 氧化苯砷晶型i、晶型ii和晶型iii及其制备方法
MX2024004055A (es) * 2021-09-30 2024-06-19 Nuo Beta Pharmaceutical Tech Shanghai Co Ltd Compuesto de oxido de fenilarsina halogenado y aplicacion del mismo.
CN116478954B (zh) * 2023-02-14 2025-06-10 中国农业大学 水稻基因OsPI4K及其在水稻抗稻瘟病中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002365110A1 (en) * 2001-07-10 2003-07-15 Massachusetts Institute Of Technology Small molecule microarrays
EP2319926B1 (en) * 2007-07-05 2016-08-31 Arrowhead Research Corporation DSRNA for treating viral infection
WO2016172952A1 (zh) * 2015-04-30 2016-11-03 江苏挪贝肽医药科技有限公司 PI4KIIIα蛋白及相关的膜蛋白复合体在治疗阿尔茨海默病中的应用
WO2019200043A1 (en) * 2018-04-11 2019-10-17 New Mexico Tech University Research Park Coporation Lipid prodrugs for use in drug delivery
EP4130014A4 (en) * 2020-03-31 2024-05-15 Nuo-Beta Pharmaceutical Technology (Shanghai) Co., Ltd. Deuterated oxophenylarsine compound and use thereof
MX2024004055A (es) * 2021-09-30 2024-06-19 Nuo Beta Pharmaceutical Tech Shanghai Co Ltd Compuesto de oxido de fenilarsina halogenado y aplicacion del mismo.

Also Published As

Publication number Publication date
KR20220071175A (ko) 2022-05-31
CN118105372A (zh) 2024-05-31
EP3995134A4 (en) 2023-07-12
WO2021004422A1 (zh) 2021-01-14
JP2022538505A (ja) 2022-09-02
IL289586A (en) 2022-03-01
EP3995134A1 (en) 2022-05-11
CA3149104A1 (en) 2021-01-14
CN114555056B (zh) 2024-01-05
TW202126294A (zh) 2021-07-16
AU2020309681A1 (en) 2022-02-24
BR112022000155A2 (pt) 2022-04-12
PE20220942A1 (es) 2022-05-31
US20230115711A1 (en) 2023-04-13
PH12022550254A1 (en) 2023-06-26
MX2022000287A (es) 2022-06-16
CN114555056A (zh) 2022-05-27

Similar Documents

Publication Publication Date Title
ECSP22047876A (es) Derivados de pirazolilo ?tiles como agentes anticancer?genos
CO2020014217A2 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CO2026004964A2 (es) Moduladores de kras
CL2020003257A1 (es) Compuestos antagonistas de pcsk9.
PY2054376A (es) Degradadores bifuncionales de brd9 y sus métodos de uso
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
CO2022017622A2 (es) Inhibidores de quinasa nek7
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
CL2021000793A1 (es) Inhibición de la proteasa 30 específica de la ubiquitina (usp30)
AR048588A1 (es) Uso de inhibidores de la fosfodiesterasa de tipo iii (pde iii) para la reduccion del tamano del corazon en mamiferos que padecen insuficiencia cardiaca
CO2024006727A2 (es) Compuestos y composiciones macrocíclicos, y métodos para preparar y utilizar los mismos
CO2022008171A2 (es) Derivado tricíclico de dihidroimidazopirimidona, método de preparación del mismo, composición farmacéutica y uso del mismo
ECSP11005768A (es) Derivados de azol-pirimidina condensados
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
MX2022000287A (es) Composición de inhibidor micromolécular de pi4kiiia, método de preparación y uso.
CR7673A (es) Antranilamidopirimidinas que inhiben vegfr-2 y vegfr-3
CO2019002555A2 (es) Composición farmacéutica
CO2022015428A2 (es) Compuesto de oxofenilarsina deuterada y uso del mismo
MX2020004179A (es) Combinacion que comprende al menos un modulador de espliceosomas y al menos un inhibidor elegido de inhibidores de bcl2, bcl2/bclxl y bclxl, y metodos de uso.
CO2022019131A2 (es) Inhibidores de la quinasa nek7
CL2025002366A1 (es) Compuesto que contiene trifluorometilsulfonilo.
CL2025000581A1 (es) Estructuras derivadas de tn3 específicas de cd40l; tratamiento, prevención del síndrome de sjögren
CO2025018537A2 (es) Formulación que comprende un conjugado anticuerpo-fármaco dirigido a claudina 18.2, método para su preparación y uso
UY38829A (es) Cannabinoides solubles en agua
MX2021007032A (es) Derivados activos de éster de testosterona, composiciones y usos de los mismos.